BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsTOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosimilar toActemra approved by USFDA GUANGZHOU, C...
GUANGZHOU,China --(PR Newswire) -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative and biosimilars, today announcedpositive Phase 1 clinical data for BAT8006 (Folate-Receptor-α-ADC) as part of apresentation of the clinical result...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced the company has reached a licensing agreement with Mega Lifesciences PCL for BAT 17 06, its bevacizumab biosimilar, under wh...
